(Q44413952)

2 December 2017

title

Amantadine increases L-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats (English)

1 reference

2 December 2017

1 reference

Akira Arai

1

1 reference

2 December 2017

Kazuya Kannari

2

1 reference

2 December 2017

Huo Shen

3

1 reference

2 December 2017

Tetsuya Maeda

4

1 reference

2 December 2017

Toshihiro Suda

5

1 reference

2 December 2017

Muneo Matsunaga

6

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

2 December 2017

1 reference

2 December 2017

volume

972

1 reference

2 December 2017

issue

1-2

1 reference

2 December 2017

page(s)

229-234

1 reference

Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Axonal sprouting following lesions of the rat substantia nigra

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Differential effects of NMDA and non-NMDA antagonists on the activity of aromatic L-amino acid decarboxylase activity in the nigrostriatal dopamine pathway of the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

The effect of amantadine on the uptake of dopamine and noradrenaline by rat brain homogenates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Amantadine attenuates response alterations resulting from repetitive L-DOPA treatment in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Amantadine increases aromatic L-amino acid decarboxylase mRNA in PC12 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Amantadine for Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-D-aspartate antagonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Treatment of Parkinson's disease with amantadine and levodopa. A one-year study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

The toxicologic and pharmacologic properties of amantadine hydrochloride.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Dopamine: Release from the Brain in vivo by Amantadine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2803%2902531-9

10.1016/S0006-8993(03)02531-9

7 January 2021

Identifiers

DOI

1 reference

2 December 2017

1 reference